Novo Nordisk A/S (NYSE:NVO) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Novo Nordisk A/S (NYSE:NVO) ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

A new study has revealed what could be happening to your muscles after taking Ozempic, though clinical trials are needed to test on humans ...

July, video editor Meng Meng, 38, has been injecting herself with a weekly weight loss drug, hoping it will finally help her ...

Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world. Collectively known as GLP-1 agonists, ...

And it’s a problem with humankind in general. We do tend to crave quick fixes, often in pharmaceutical form. That’s why Henry Dimbleby, a food campaigner and founder of Leon, called Ozempic “the ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.